Podcasts about hif ph

HIF-PH阻害薬の薬効評価 （解　説）眞仁会横須賀クリニック 診療部長　内田啓子氏 （ききて）防衛医科大学校教授　池脇克則氏

Visit nascentmc.com/podcast for full show notes Winrevair for PAH: Sotatercept-csrk (Winrevair) is FDA-approved for treating adults with pulmonary arterial hypertension (PAH), enhancing exercise capacity, improving WHO functional class, and reducing clinical worsening events. It's the first FDA-approved activin signaling inhibitor for PAH, addressing the imbalance in vascular cell proliferation underlying the condition. The approval is based on the Phase 3 STELLAR trial, demonstrating significant improvements in walk distance and reduced risk of clinical worsening events [1]. Vafseo for CKD: Vadadustat (Vafseo) is approved for managing anemia due to chronic kidney disease (CKD) in adult dialysis patients. As an oral HIF-PH inhibitor, it stimulates endogenous erythropoietin production, offering a novel approach to anemia management. Approval is supported by efficacy and safety data from the INNO2VATE program and post-marketing safety data from Japan [2]. Ultomiris for NMOSD: Ravulizumab-cwvz (Ultomiris) is FDA-approved for treating neuromyelitis optica spectrum disorder (NMOSD) in patients with anti-AQP4 antibodies. It's a terminal complement C5 inhibitor administered once every two months, demonstrating efficacy in preventing relapses. Approval is based on the Phase 3 CHAMPION-NMOSD study, showing significant reductions in relapse risk compared to placebo [3]. Evolut FX+ for TAVR: The Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system is FDA-approved for treating symptomatic severe aortic stenosis. It features enhancements for improved catheter maneuverability without compromising effectiveness. The approval expands treatment options for patients across all risk categories [4]. Vemlidy for Pediatric HBV: Tenofovir alafenamide (Vemlidy) is FDA-approved for treating chronic hepatitis B virus (HBV) infection in pediatric patients aged 6 years and older with compensated liver disease. It's a preferred or first-line treatment option, addressing a significant medical need. Approval is based on the Phase 2 clinical trial 1092, demonstrating efficacy and safety in this patient population [5]. Pemgarda for COVID: Pemgarda, a monoclonal antibody, is FDA-approved for preventive use in immunocompromised individuals aged 12 and older against COVID-19. It prevents virus attachment and has shown promising results in reducing symptomatic COVID-19 cases. Approval is based on emergency use authorization and preliminary data from the CANOPY Phase 3 clinical trial [6].

CME credits: 0.25 Valid until: 15-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/emerging-treatment-for-anemia-of-ckd-hif-ph-inhibitors/16089/ In this activity, Dr. Jay Wish, Chief Medical Officer for Outpatient Dialysis in the Division of Nephrology at Indiana University Health, discusses emerging treatment for Anemia of chronic kidney disease (CKD), specifically with hypoxia-inducible factor–prolyl hydroxylase domain (HIF-PH) inhibitors.=

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/navigating-ckd-podcast#group-tabs-node-course-default1To facilitate timely diagnosis and rapid treatment initiation for anemia in CKD, the multidisciplinary and interprofessional CKD-anemia treatment team should be aware of the significant impact of anemia on patient quality of life, progression of CKD, and cardiovascular events. Erythropoietin-stimulating agents (ESAs) are associated with significant cardiovascular safety-related concerns, but the emergence of the oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) may improve erythropoiesis without the undesirable downstream effects of ESAs. However, HIF-PHIs place in therapy has not yet been fully elucidated. Here, join the interprofessional team of Dr. Ajay Singh, Dr. Jane Davis, and Dr. Calvin Meaney as they explore an incisive review of current CKD-anemia treatment and diagnostic challenges, as well as the evidentiary base for HIF-PHI utilization in CKD-anemia that establishes context for the future of these agents. In conclusion, a practical discussion of real-world patient case scenarios will be presented, to provide learners with context of the multiple comorbidities, complexities, diagnostic challenges, and barriers to appropriate treatment of CKD-anemia.

Introduction of moderator, faculty, and disclosures by Todd: ­We have an incredible discussion coming up with our moderator, Dr. Jessica Kerr, Professor and Clinical Pharmacy Specialist – Cardiometabolic at the Southern Illinois University Edwardsville School of Pharmacy in Illinois and Dr. Joanna Hudson, who is a tenured Professor in the Department of Clinical Pharmacy and Translational Science and the Department of Medicine (Division of Nephrology) at the University of Tennessee (UT) Health Science Center and a Clinical Pharmacist specializing in nephrology at Methodist Hospital in Memphis, TN. They will provide a brief overview of anemia in chronic kidney disease and highlight updates and advancements in the development of some of the emerging agents used.  If you haven't listened to the three other webinars in this learning series on anemia in chronic kidney disease, be sure to check them out at pharmacytimes.org. Outline updates and advancements in the development of HIF-PH inhibitors for anemia in chronic kidney disease.   Express the role of the pharmacist in managing anemia in CKD through early detection and coordination of care.    Guests:    Dr. Jessica Kerr PharmD Interim Associate Dean - Office of Professional and Student Affairs at Southern Illinois University Edwardsville   Dr. Joanna Hudson PharmD Professor at University of Tennessee Health Science Center Learn more about your ad choices. Visit megaphone.fm/adchoices

Introduction of moderator, faculty, and disclosures by Todd: ­We have an incredible discussion coming up with our moderator, Dr. Jessica Kerr, Professor and Clinical Pharmacy Specialist – Cardiometabolic at the Southern Illinois University Edwardsville School of Pharmacy in Illinois and Dr. Joanna Hudson, who is a tenured Professor in the Department of Clinical Pharmacy and Translational Science and the Department of Medicine (Division of Nephrology) at the University of Tennessee (UT) Health Science Center and a Clinical Pharmacist specializing in nephrology at Methodist Hospital in Memphis, TN. They will provide a brief overview of anemia in chronic kidney disease and highlight updates and advancements in the development of some of the emerging agents used.  If you haven't listened to the three other webinars in this learning series on anemia in chronic kidney disease, be sure to check them out at pharmacytimes.org. Outline updates and advancements in the development of HIF-PH inhibitors for anemia in chronic kidney disease.   Express the role of the pharmacist in managing anemia in CKD through early detection and coordination of care.    Guests:    Dr. Jessica Kerr PharmD Interim Associate Dean - Office of Professional and Student Affairs at Southern Illinois University Edwardsville   Dr. Joanna Hudson PharmD Professor at University of Tennessee Health Science Center Learn more about your ad choices. Visit megaphone.fm/adchoices

Introduction of moderator, faculty, and disclosures by Todd: ­We have an incredible discussion coming up with our moderator, Dr. Jessica Kerr, Professor and Clinical Pharmacy Specialist – Cardiometabolic at the Southern Illinois University Edwardsville School of Pharmacy in Illinois and Dr. Joanna Hudson, who is a tenured Professor in the Department of Clinical Pharmacy and Translational Science and the Department of Medicine (Division of Nephrology) at the University of Tennessee (UT) Health Science Center and a Clinical Pharmacist specializing in nephrology at Methodist Hospital in Memphis, TN. They will provide a brief overview of anemia in chronic kidney disease and highlight updates and advancements in the development of some of the emerging agents used.  If you haven't listened to the three other webinars in this learning series on anemia in chronic kidney disease, be sure to check them out at pharmacytimes.org. Outline updates and advancements in the development of HIF-PH inhibitors for anemia in chronic kidney disease.   Express the role of the pharmacist in managing anemia in CKD through early detection and coordination of care.    Guests:    Dr. Jessica Kerr PharmD Interim Associate Dean - Office of Professional and Student Affairs at Southern Illinois University Edwardsville   Dr. Joanna Hudson PharmD Professor at University of Tennessee Health Science Center Learn more about your ad choices. Visit megaphone.fm/adchoices

「HIF-PH阻害薬」（解説）埼玉医科大学総合医療センター 腎・高血圧内科 教授　　長谷川元氏（ききて）防衛医科大学校教授　　池脇克則氏

FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss the start of Q2 earnings season, including the receding impact of COVID-19 on drug sales and Biogen's claim of a misinformation conspiracy designed to derail adoption of Aduhelm. Also under the spotlight is the HIF-PH drug class and new cardiovascular data from Cytokinetics.

Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/HBK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live web broadcast, a multidisciplinary panel explores the latest data for HIF-PH inhibitors and examines their efficacy and safety in treating anemia in patients with chronic kidney disease (CKD). The panel also shares evidence-based strategies and describes new models of care for managing patients with CKD-associated anemia, as well as offers practical insight on how clinical pharmacists may take an active role in improving clinical outcomes in patients with CKD. Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Differentiate the mechanisms of action of current and emerging treatments for anemia associated with CKD, Recognize the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia associated with CKD in both nondialysis- and dialysis-dependent patients, Apply evidence-based strategies to effectively coordinate with the healthcare team to identify patients with anemia-associated CKD who would likely derive benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HBK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live web broadcast, a multidisciplinary panel explores the latest data for HIF-PH inhibitors and examines their efficacy and safety in treating anemia in patients with chronic kidney disease (CKD). The panel also shares evidence-based strategies and describes new models of care for managing patients with CKD-associated anemia, as well as offers practical insight on how clinical pharmacists may take an active role in improving clinical outcomes in patients with CKD. Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Differentiate the mechanisms of action of current and emerging treatments for anemia associated with CKD, Recognize the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia associated with CKD in both nondialysis- and dialysis-dependent patients, Apply evidence-based strategies to effectively coordinate with the healthcare team to identify patients with anemia-associated CKD who would likely derive benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HBK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live web broadcast, a multidisciplinary panel explores the latest data for HIF-PH inhibitors and examines their efficacy and safety in treating anemia in patients with chronic kidney disease (CKD). The panel also shares evidence-based strategies and describes new models of care for managing patients with CKD-associated anemia, as well as offers practical insight on how clinical pharmacists may take an active role in improving clinical outcomes in patients with CKD. Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Differentiate the mechanisms of action of current and emerging treatments for anemia associated with CKD, Recognize the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia associated with CKD in both nondialysis- and dialysis-dependent patients, Apply evidence-based strategies to effectively coordinate with the healthcare team to identify patients with anemia-associated CKD who would likely derive benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HBK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live web broadcast, a multidisciplinary panel explores the latest data for HIF-PH inhibitors and examines their efficacy and safety in treating anemia in patients with chronic kidney disease (CKD). The panel also shares evidence-based strategies and describes new models of care for managing patients with CKD-associated anemia, as well as offers practical insight on how clinical pharmacists may take an active role in improving clinical outcomes in patients with CKD. Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Differentiate the mechanisms of action of current and emerging treatments for anemia associated with CKD, Recognize the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia associated with CKD in both nondialysis- and dialysis-dependent patients, Apply evidence-based strategies to effectively coordinate with the healthcare team to identify patients with anemia-associated CKD who would likely derive benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HBK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live web broadcast, a multidisciplinary panel explores the latest data for HIF-PH inhibitors and examines their efficacy and safety in treating anemia in patients with chronic kidney disease (CKD). The panel also shares evidence-based strategies and describes new models of care for managing patients with CKD-associated anemia, as well as offers practical insight on how clinical pharmacists may take an active role in improving clinical outcomes in patients with CKD. Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Differentiate the mechanisms of action of current and emerging treatments for anemia associated with CKD, Recognize the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia associated with CKD in both nondialysis- and dialysis-dependent patients, Apply evidence-based strategies to effectively coordinate with the healthcare team to identify patients with anemia-associated CKD who would likely derive benefit from treatment with a HIF-PH inhibitor.